Drug
AVM0703
AVM0703 is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph phase_1
2
67%
Phase Distribution
2
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 1Safety & dosage
2(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
0.0%
0 of 0 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Other(1)
Detailed Status
Not yet recruiting1
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 1
Trials by Phase
Phase 12 (100.0%)
Trials by Status
not_yet_recruiting133%
recruiting133%
unknown133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_1
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
NCT04329728
not_yet_recruitingphase_1
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
NCT04366115
unknown
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
NCT05974410
Clinical Trials (3)
Showing 3 of 3 trials
NCT04329728Phase 1
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies
NCT04366115Phase 1
Evaluating AVM0703 for Treatment of COVID-19 or Influenza-mediated ARDS
NCT05974410
Expanded Access to Immunomodulatory AVM0703 for Solid Tumor and Blood Cancer Patients
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3